Fig. 5
From: CanSeer: a translational methodology for developing personalized cancer models and therapeutics
Therapeutic assessment in patients with lung squamous cell carcinoma (LUSC). The variability in patient-specific response to different drugs and combinations are shown. (A) The therapeutic response indices (TRI) of seven patients are plotted for 50/149 drug combinations in alphabetical order. To demonstrate the response of an individual patient against various drugs and combinations, TRI, proliferative indices and apoptotic indices has been plotted here for only 30 combinations (see patient therapy files in supplementary 14A, B and C for individual responses to 149 drugs/drug combinations). For “patient ID: TCGA-22–5471”, (B) Osimertinib + APR-246 showed highest TRI, (C) Afuresertib + KU-55933 exhibited lowest proliferative index, and (D) Ulixertinib + Ibrutinib indicated highest apoptotic index (For individual patient results, see “Patient Therapy File” in S14A, B and C).
